About: Regulatory Consideration on Preparation and Clinical Use of COVID-19 Convalescent Plasma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Regulatory Consideration on Preparation and Clinical Use of COVID-19 Convalescent Plasma Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Regulatory Consideration on Preparation and Clinical Use of COVID-19 Convalescent Plasma
Creator	Abdullahöztürk, Mehmet Azap, Alpay Ertugrulörüç, Nigar Gündüz, Ahmet Gündüz, Mehmet Tekin, Tekin, Ahmet Yenicesu, İdil Yılmaz, Soner
Source	Elsevier; Medline; PMC
abstract	Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19), spreading from Wuhan to worldwide has been emerged since December 2019. Although scientists and researchers have been racing to develop specific therapeutic agents or vaccines against SARS-CoV-2 since the identification of the agent, either a drug or a vaccine has not been approved to treat or to prevent COVID-19 up to date. On the base of historical experiences, Convalescent Plasma (CP), a passive antibody therapy, has been evaluated as a hopeful and potential therapeutic option since the beginning of the COVID-19 outbreak. Immune plasma had been used previously for the treatment of H1N1 influenza virus, SARS-CoV-1 and MERS-CoV epidemics successfully. In this scope competent authorities are responsible to set up certain principles and criteria for the collection and clinical use of COVID-19 Convalescent Plasma (CCP). This document has been prepared to aid both for the convalescent plasma suppliers and the clinicians. The first part encompasses the supply of CCP and the second part lead the clinical use of CCP for the treatment of patients with severe COVID-19 infection. Turkish Ministry of Health developed a guide on collection and clinical use of CCP and created a web-based monitoring system to follow-up the patients treated with convalescent plasma in universal. This follow-up process is thought to be crucial for the creation and development of current and future treatment modalities. This guide would be a pathfinder for clinicians and/or institutions those eager to conduct CCP treatment more effectively.
has issue date	2020-06-04(xsd:dateTime)
bibo:doi	10.1016/j.transci.2020.102846
bibo:pmid	32593519
has license	els-covid
sha1sum (hex)	fbecc52ccfa31586453dc22e2757f9bb68c9c6e8
schema:url	https://doi.org/10.1016/j.transci.2020.102846
resource representing a document's title	Regulatory Consideration on Preparation and Clinical Use of COVID-19 Convalescent Plasma
has PubMed Central identifier	PMC7271837
has PubMed identifier	32593519
schema:publication	Transfus Apher Sci
resource representing a document's body	covid:fbecc52ccfa31586453dc22e2757f9bb68c9c6e8#body_text
is schema:about of	named entity 'base' named entity 'develop' named entity 'vaccines' named entity 'racing' named entity 'plasma' named entity 'plasma' named entity 'COVID-19' named entity 'severe' named entity 'CCP' named entity 'influenza' named entity 'therapeutic' named entity 'MERS-CoV' named entity 'lead' named entity 'COVID-19' named entity 'Convalescent Plasma' named entity 'therapeutic agents' named entity 'plasma' named entity 'COVID' named entity 'Convalescent Plasma' named entity 'convalescent plasma therapy' named entity 'Istanbul' named entity 'family of viruses' named entity 'common cold' named entity 'follow-up' named entity 'COVID' named entity 'supportive therapy' named entity 'neutralizing antibody' named entity 'H1N1' named entity '2019-nCoV' named entity 'World Health Organization' named entity 'Turkey' named entity 'convalescent plasma' named entity 'posed a threat' named entity 'vaccine' named entity 'plasma' named entity 'infection' named entity 'therapeutic purposes' named entity 'ISBT 128' named entity 'TRC' named entity 'antibodies' named entity 'neutralizing antibody' named entity 'acute lung injury' named entity 'COVID-19 pandemic' named entity 'COVID' named entity 'COVID' named entity 'SARS CoV' named entity 'critically ill patients' named entity 'WHO' named entity 'plasma' named entity 'MERS-CoV' named entity 'plasma' named entity '2019-nCoV' named entity 'Plasma' named entity 'public health emergency' named entity '28 days' named entity 'fatality rate' named entity 'neutralizing antibody' named entity 'Severe Acute Respiratory Syndrome' named entity '28 February 2020' named entity 'Ankara' named entity 'plasma' named entity 'transfusion' named entity 'blood donation' named entity '11 March 2020' named entity 'respiratory infections' named entity 'Serum' named entity 'pathogen inactivation' named entity 'infectious disease specialist' named entity 'severe diseases' named entity 'Plasma' named entity 'plasma or serum' named entity 'TRC' named entity 'Coronaviruses'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software